Effects of selective MMP-13 inhibition in squamous cell carcinoma depend on estrogen

International Journal of Cancer

Volumn 135, Issue 12, 2014, Pages 2749-2759

  Meides, Alice ^a   Gutschalk, Claudia M ^a   Devel, Laurent ^b   Beau, Fabrice ^b   Czarny, Bertrand ^b   Hensler, Sabine ^c   Neugebauer, Julia ^a   Dive, Vincent ^b   Angel, Peter ^a   Mueller, Margareta M ^a,c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b DIF   (France)

^c FURTWANGEN UNIVERSITY   (Germany)

Author keywords

Angiogenesis; Invasion; MMP 13; SCC

Indexed keywords

COLLAGENASE 3; ESTRADIOL; ESTROGEN; MATRIX METALLOPROTEINASE INHIBITOR; VASCULOTROPIN A;

ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CARCINOMA, SQUAMOUS CELL; CYTOLOGY; ENZYMOLOGY; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; KERATINOCYTE; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; SKIN NEOPLASMS; TIME; TUMOR INVASION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; ESTRADIOL; ESTROGENS; EXTRACELLULAR MATRIX; FEMALE; FIBROBLASTS; KERATINOCYTES; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE INHIBITORS; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; SKIN NEOPLASMS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84908877373     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28866     Document Type: Article

References (49)

1. Ala-aho R, Kahari VM. Collagenases in cancer. Biochimie 2005;87:273-86.
2. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003;200:448-64.
3. Masson V, de la Ballina LR, Munaut C, et al. Contribution of host MMP-2 and MMP-9 topromote tumor vascularization and invasion of malignant keratinocytes. FASEB J 2005;19: 234-6.
4. Overall CM, Kleifeld O. Tumour microenvironment- opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227-39.
5. Hashimoto G, Inoki I, Fujii Y, et al. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem 2002;277:36288-95.
6. Hattori N, Mochizuki S, Kishi K, et al. MMP-13plays a role in keratinocyte migration, angiogene-sis, and contraction in mouse skin wound healing. Am J Pathol 2009;175:533-46.
7. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011;41:271-90.
8. Murray GI, Duncan ME, O'Neil P, et al. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998;185: 256-61.
9. Kemik O, Kemik AS, Sumer A, et al. Levels of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 in gastric cancer. World J Gastroenterol 2011;17:2109-12.
10. Poola I, DeWitty RL, Marshalleck JJ, et al. Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat Med 2005;11:481-3.
11. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
12. Nielsen BS, Rank F, Lopez JM, et al. Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. Cancer Res 2001;61:7091-100.
13. Luukkaa M, Vihinen P, Kronqvist P, et al. Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer. Head Neck 2006;28:225-34.
14. Airola K, Karonen T, Vaalamo M, et al. Expression of collagenases-1 and 23 and their inhibitors TIMP-1 and 2 3 correlates with the level of invasion in malignant melanomas. Br J Cancer 1999;80:733-43.
15. Airola K, Johansson N, Kariniemi AL, et al. Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J Investig Dermatol 1997;109:225-31.
16. Lederle W, Hartenstein B, Meides A, et al. MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Carcinogenesis 2010;31:1175-84.
17. Pendas AM, Uria JA, Jimenez MG, et al. An overview of collagenase-3 expression in malignant tumors and analysis of its potential value as a target in antitumor therapies. Clin Chim Acta 2000; 291:137-55.
18. Johansson N, Ala-aho R, Uitto V, et al. Expression of collagenase-3 (MMP-13) and collagenase- 1 (MMP-1) by transformed keratinocytes isdependent on the activity of p38 mitogenactivated protein kinase. J Cell Sci 2000;113(Pt 2): 227-35.
19. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-49.
20. Hartenstein B, Dittrich BT, Stickens D, et al. Epidermal development and wound healing inmatrix metalloproteinase 13-deficient mice. J Investig Dermatol 2006;126:486-96.
21. Kivisaari AK, Kallajoki M, Ala-aho R, et al. Matrix metalloproteinase-7 activates heparinbinding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma. Br J Dermatol 2010;163:726-35.
22. Balbin M, Fueyo A, Knauper V, et al. Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J Biol Chem 2001;276: 10253-62.
23. Vosseler S, Lederle W, Airola K, et al. Distinct progression-associated expression of tumor and stromal MMPs in HaCaT skin SCCs correlates with onset of invasion. Int J Cancer 2009;125: 2296-306.
24. Devel L, Czarny B, Beau F, et al. Third generation of matrix metalloprotease inhibitors: gain in selectivity by targeting the depth of the S10 cavity. Biochimie 2010;92:1501-8.
25. Engel CK, Pirard B, Schimanski S, et al. Structural basis for the highly selective inhibition of MMP-13. Chem Biol 2005;12:181-9.
26. Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2003;2:S127-33.
27. Fusenig NE, Amer SM, Boukamp P, et al. Characteristics of chemically transformed mouse epidermal cells in vitro and in vivo. Bulletin du Cancer 1978;65:271-9.
28. Todaro GJ, Green H. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J Cell Biol 1963;17:299-313.
29. Stacey A, Doyle A. Routine testing of cell cultures and their products for mycoplasma contamination. Methods Mol Biol 1997;75:305-11.
30. Devel L, Rogakos V, David A, et al. Development of selective inhibitors and substrate of matrix metalloproteinase-12. J Biol Chem 2006;281: 11152-60.
31. Obermueller E, Vosseler S, Fusenig NE, et al. Cooperative autocrine and paracrine functions of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the progression of skin carcinoma cells. Cancer Res 2004;64:7801-12.
32. Langbein L, Rogers MA, Praetzel S, et al. Characterization of a novel human type II epithelial keratin K1b, specifically expressed in eccrine sweat glands. J Investig Dermatol 2005;125:428-44.
33. Boyd S, Virolainen S, Parssinen J, et al. MMP-10 (Stromelysin-2) and MMP-21 in human and murine squamous cell cancer. Exp Dermatol 2009;18:1044-52.
34. Kassira N, Glassberg MK, Jones C, et al. Estrogen deficiency and tobacco smoke exposure promotematrix metalloproteinase-13 activation in skin of aging B6 mice. Ann Plast Surg 2009;63:318-22.
35. Lu T, Achari Y, Sciore P, et al. Estrogen receptor alpha regulates matrix metalloproteinase-13 promoter activity primarily through the AP-1 transcriptional regulatory site. Biochim Biophys Acta 2006;1762:719-31.
36. Bendrik C, Karlsson L, Dabrosin C. Increased endostatin generation and decreased angiogenesis via MMP-9 by tamoxifen in hormone dependent ovarian cancer. Cancer Lett 2010;292:32-40.
37. Clements D, Asprey SL, McCulloch TA, et al. Analysis of the oestrogen response in an angiomyolipoma derived xenograft model. Endocrine- Relat Cancer 2009;16:59-72.
38. Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005;26:1657-67.
39. Karagas MR, Nelson HH, Sehr P, et al. Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst 2006;98:389-95.
40. Edwards D, Hoyer-Hansen G, Blasi F, et al., Third generation MMP inhibitors: recent advances in the development of highly selective inhibitors. The Cancer Degradome, Ed. D. Edwards Springer, 2008.
41. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;24:4783-91.
42. Russo J, Russo IH. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 2006;102:89-96.
43. Mancuso M, Gallo D, Leonardi S, et al. Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer. Carcinogenesis 2009;30:340-7.
44. WeyantMJ, Carothers AM, Mahmoud NN, et al. Reciprocal expression of ERalpha and ERbeta is associated with estrogen-mediated modulation of intestinal tumorigenesis. Cancer Res 2001;61:2547-51.
45. Grodstein F, Martinez ME, Platz EA, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 1998;128: 705-12.
46. Verdier-Sevrain S, Bonte F, Gilchrest B. Biology of estrogens in skin: implications for skin aging. Exp Dermatol 2006;15:83-94.
47. Balbin M, Fueyo A, Tester AM, et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003;35:252-7.
48. Inoki I, Shiomi T, Hashimoto G, et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGFinduced angiogenesis. FASEB J 2002;16:219-21.
49. Merlo S, Sortino MA. Estrogen activates matrix metalloproteinases-2 and 29 to increase beta amyloid degradation. Mol Cell Neurosci 2012;49:423-9.